Pikachu, Snorlax Named Official Sleep Support Ambassadors; Move by Health, Labor and Welfare Ministry Aims to Encourage Healthy Rest
The Health, Labor and Welfare Ministry spearheaded this initiative, which leverages the appeal of these iconic figures to encourage people, especially children, to develop better sleep habits.
The characters are expected to participate in various public awareness events, adding a fun, recognizable element to the important message that everyone needs to get enough sleep.
The ministry recommends nine to 12 hours of sleep for elementary students, and eight to 10 hours for junior and high school students, to maintain good health.
Since last fiscal year, the ministry has been collaborating with the Pokemon Company, which publishes 'Pokemon Sleep,' a smartphone game that tracks the user's sleep. Together, they have created brochures and other materials to encourage adequate sleep.
On Thursday, the day of the announcement, Snorlax and a nightcapped Pikachu visited the ministry and received their letters of appointment from Health, Labor and Welfare Minister Takamaro Fukuoka.
'We hope to continue working with the health ministry to positively change sleep habits,' said Pokemon Company Representative Director Takato Utsunomiya.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yomiuri Shimbun
a day ago
- Yomiuri Shimbun
New Pharmaceuticals Overseas: Change Situation in Which Foreign Drugs are Not Available in Japan
If groundbreaking new drugs are available overseas but cannot be used in Japan, it puts many patients at a disadvantage. This situation must be changed immediately. Cases referred to as 'drug loss,' in which pharmaceuticals newly approved in other countries do not become available in Japan, are increasing. For some time now, new drugs developed by overseas pharmaceutical companies have tended to face delays in being introduced to Japan, due to this country's complicated application procedures for approval and additional clinical trials targeting Japanese patients. This problem has been dubbed 'drug lag.' The government's efforts to proceed with measures, such as strengthening the review system, have reduced delays. Instead of drug lag, however, there is now an increase in cases of drug loss. This is because more overseas companies have not even applied for approval of their products in Japan in recent years, making the situation even more serious. Behind this lies a drastic change in development methods for pharmaceuticals. Advances in life sciences have led to the production of complex biopharmaceuticals using genes and cells, shifting the primary developers from major pharmaceutical manufacturers to emerging companies. Many of them are small businesses, so they are not adequately established to expand globally. Furthermore, in Japan, there is a strong tendency to lower the prices of drugs to curb medical expenses. This may lead many overseas drugmakers to make a business decision that there is little advantage to paying the high costs required to enter the Japanese market. Traditionally, drug loss has been conspicuous for rare ailments and pediatric diseases. However, now that the problem will likely expand to more common diseases such as breast cancer and diabetes, it is feared that patients in Japan will be unable to widely benefit from new drugs that are available overseas. To bring drugs developed overseas to Japan, it is necessary to provide more information to drugmakers and lower hurdles to applying for approval in Japan. To support U.S. companies in their applications, the Health, Labor and Welfare Ministry has established an office in the United States to assist them with the review process. It is also essential to establish a system that maintains prices that reflect the value of new pharmaceuticals. In addition to attracting overseas makers, this would also promote technological innovation in the pharmaceutical industry as a whole. However, public health cannot be steadily protected in Japan through an approach that relies on overseas companies. It is necessary to increase the number of new drugs originating in Japan. Japan's research capabilities are not low, but universities and other institutions find it difficult to directly link their research results to businesses, and this environment is hindering the improvement of pharmaceutical development capabilities. In the United States, many universities, startups and investors are concentrated in Boston to work together to produce a steady stream of new drugs. In Japan as well, it is important to create a similar hub, described as an ecosystem, for advanced academic-industrial collaboration. (From The Yomiuri Shimbun, July 28, 2025)
Japan Times
a day ago
- Japan Times
Health bureaus' inconsistencies on regenerative medicine plans spark outcry
Inconsistencies have emerged in the decisions of Japan's regional health and welfare bureaus on whether to approve regenerative medicine plans compiled by medical institutions before the commencement of treatment, according to informed sources. In one case, a regenerative medicine program was approved immediately by a regional health and welfare bureau but the same treatment plan was rejected by a different bureau. The health ministry says, however, that it uses a common manual for approving such treatment plans.
Yomiuri Shimbun
3 days ago
- Yomiuri Shimbun
Japan's Decennial Survey of Hibakusha to No Longer Be Conducted; Atomic Bomb Survivors' Average Age Cited
A government survey of hibakusha atomic bomb survivors conducted every 10 years since 1965 will not be held this year, according to the Health, Labor and Welfare Ministry. The only survey conducted nationwide by the government concerning hibakusha was used to learn about their circumstances, and the 2015 edition will be the last. Its other purpose was to help pass the experiences of hibakusha on to future generations. A survey was originally planned to be conducted this year, the 80th anniversary of the atomic bombings, but the ministry decided to end it following internal discussions. It cited 'the burden of responding to the survey on the part of hibakusha, whose average age exceeds 85,'as a reason for the cancelation. The ministry's decision to end the survey was conveyed to all the prefectures and the two cities of Hiroshima and Nagasaki in December. As of the end of March, there were 99,130 people nationwide who hold a hibakusha health book, with an average age of 86.13. 'The fact-finding survey on A-bomb survivors' started in 1965, 20 years after the atomic bombs were dropped on Hiroshima and Nagasaki, by the then Health and Welfare Ministry. It was aimed at comprehensively assessing the health conditions of hibakusha, with its findings to be utilized for taking measures to support them, including through the provision of allowances. Through 2015, the six surveys were conducted with the cooperation of all prefectures and the two cities. The first four surveys, through 1995, covered all those who had hibakusha health books, ranging from 270,000 to 360,000 people, with inquiries made either through in-person visits or by post. The following two surveys covered a random sample of 50,000 to 60,000 hibakusha. Each survey asked hibakusha about their age, place of residence, lifestyle and health conditions. The surveys found that a conspicuous number of hibakusha were bedridden or were in need. They also revealed experiences of discrimination in employment and marriage and concerns about the health of children and grandchildren — called second- and third-generation hibakusha. These findings have been utilized by the government to extend tailored support to hibakusha. From the 1995 survey, a section was included for hibakusha to be able to describe their experiences freely. A total of 104,312 accounts were collected through the survey.
